Nat Rev Cancer. 2007 Jun;7(6):441-53.

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Source

Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. j.melo@imperial.ac.uk

Abstract

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?

PMID:: 17522713; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Fusion Proteins, bcr-abl

LinkOut - more resources

Full Text Sources

Supplemental Content

Related citations

Review Chronic myelogenous leukemia: mechanisms underlying disease progression. [Leukemia. 2002]
Review Chronic myelogenous leukemia: mechanisms underlying disease progression.
Shet AS, Jahagirdar BN, Verfaillie CM. Leukemia. 2002 Aug; 16(8):1402-11.
Review Chronic myeloid leukemia stem cells. [Hematology Am Soc Hematol Educ Program. 200...]
Review Chronic myeloid leukemia stem cells.
Jamieson CH. Hematology Am Soc Hematol Educ Program. 2008; :436-42.
Regulation of myeloid leukaemia by the cell-fate determinant Musashi. [Nature. 2010]
Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, et al. Nature. 2010 Aug 5; 466(7307):765-8. Epub 2010 Jul 18.
RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression. [J Hematol Oncol. 2009]
RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.
Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, Voralia M, Czader M, DeCoteau JF, Geyer CR. J Hematol Oncol. 2009 Jul 14; 2:28. Epub 2009 Jul 14.
Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia. [Blood. 2009]
Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
Miyazaki K, Yamasaki N, Oda H, Kuwata T, Kanno Y, Miyazaki M, Komeno Y, Kitaura J, Honda Z, Warming S, et al. Blood. 2009 May 7; 113(19):4702-10. Epub 2009 Feb 20.

See reviews... See all...

Cited by 37 PubMed Central articles

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. [BMC Cancer. 2011]
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Chai JH, Zhang Y, Tan WH, Chng WJ, Li B, Wang X. BMC Cancer. 2011 Dec 9; 11:512. Epub 2011 Dec 9.
p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. [Haematologica. 2012]
p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M. Haematologica. 2012 Feb; 97(2):251-7. Epub 2011 Nov 4.
Myc roles in hematopoiesis and leukemia. [Genes Cancer. 2010]
Myc roles in hematopoiesis and leukemia.
Delgado MD, León J. Genes Cancer. 2010 Jun; 1(6):605-16.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Nat Rev Cancer. 2007 Jun ;7(6):441-53.

PubMed
Derivative chromosome 1 and GLUT1 deficiency syndrome in a sibling pair.
Derivative chromosome 1 and GLUT1 deficiency syndrome in a sibling pair.
Mol Cytogenet. 2010 May 28 ;3(1):10.

PubMed
Molecular cytogenetic characterization of a complex rearrangement involving chro...
Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia.
Cancer Genet Cytogenet. 2002 Jul 15 ;136(2):141-5.

PubMed
Validation and implementation of array comparative genomic hybridisation as a fi...
Validation and implementation of array comparative genomic hybridisation as a first line test in place of postnatal karyotyping for genome imbalance.
Mol Cytogenet. 2010 Apr 15 ;3:9.

PubMed
Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic mye...
Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines.
Mol Cytogenet. 2010 Sep 1 ;3:15.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Libraries

Supplemental Content

Related citations

Cited by 37 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information